Citations

Clear

861 citation(s) found for "Sd, Wexner".

Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Fakhoury, Kareem , Rusthoven, Chad G. , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Peterson, Jennifer , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Deibert, Christopher P., Prasad, Rahul N. , Raval, Raju R. , Patel, Samir , Franzini, Andrea , Attuati, Luca , Mathieu, David , Trudel, Claire, Lee, Cheng-chia, Green, Sheryl , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Peterson, Jennifer L., Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Picozzi, Piero , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | October 18, 2022 | Volume: 91 | Issue: 6 | Pages: 872-882

10.1227/neu.0000000000002127 | PMID 36255215 Get It

BACKGROUND: Melanoma brain metastases are commonly treated with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs). However, the toxicity of these 2 treatments is largely unknown when administered concurrently. OBJECTIVE: To evaluate the risk of radiation necrosis (RN) with concurrent and nonconcurrent SRS and ICIs. METHODS: The guidelines from the Strengthening the Reporting of Observational Studies in Epidemiology checklist were used. Inverse probability of treatment weighting, univariable and multivariable logistic regression, and the Kaplan-Meier method was utilized. RESULTS: There were 203 patients with 1388 brain metastases across 11 international institutions in 4 countries with a median follow-up of 15.6 months. The rates of symptomatic RN were 9.4% and 8.2% in the concurrent and nonconcurrent groups, respectively ( P =.766). On multivariable logistic regression, V12 ≥ 10 cm 3 (odds ratio [OR]: 2.76; P =.006) and presence of BRAF mutation (OR: 2.20; P =.040) were associated with an increased risk of developing symptomatic RN; the use of concurrent over nonconcurrent therapy was not associated with an increased risk (OR: 1.06; P =.877). There were 20 grade 3 toxic events reported, and no grade 4 events reported. One patient experienced a grade 5 intracranial hemorrhage. The median overall survival was 36.1 and 19.8 months for the concurrent and nonconcurrent groups (log-rank P =.051), respectively. CONCLUSION: Concurrent administration of ICIs and SRS are not associated with an increased risk of RN. Tumors harboring BRAF mutation, or perhaps prior exposure to targeted agents, may increase this risk. Radiosurgical optimization to maintain V12 < 10 cm 3 is a potential strategy to reduce the risk of RN.
Implantable Peripheral Nerve Stimulation for Peripheral Neuropathic Pain: A Systematic Review of Prospective Studies
Char, Steven , Jin, Max Y. , Francio, Vinicius Tieppo , Hussain, Nasir , Wang, Eric J. , Morsi, Mahmoud , Orhurhu, Vwaire , Fink, Adam, D’Souza, Ryan S. , D'Souza, Ryan S , Tieppo Francio, Vinicius , Wang, Eric , Prokop, Larry J. , Fink, Adam

Mayo Clinic

Biomedicines | October 17, 2022 | Volume: 10 | Issue: 10 | Pages: 2606

10.3390/biomedicines10102606 | PMID 36289867 Get It

Peripheral nerve stimulation (PNS) has been utilized for over 50 years with accumulating evidence of efficacy in a variety of chronic pain conditions. The level and strength of evidence supporting the use of PNS for peripheral neuropathic pain remains unclear. The purpose of this review is to synthesize data from prospective studies on the efficacy of PNS for neuropathic pain as it pertains to pain intensity, neurological deficits/neuropathy (e.g., weakness, sensory deficits, gait/balance), and other secondary outcomes (quality of life, satisfaction, emotional functioning, and adverse events). In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this review identified articles from MEDLINE(R), EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Overall, per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, pooled results demonstrate very low quality or low quality of evidence supporting modest to substantial improvement in pain and neurological function after PNS implantation for treatment of peripheral neuropathic pain. PNS for phantom limb pain was the only indication that had moderate level evidence. Future prospective and well-powered studies are warranted to assess the efficacy of PNS for peripheral neuropathic pain.
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
Krysiak, Kilannin , Danos, Arpad , McMichael, Joshua F. , Coffman, Adam , Kiwala, Susanna , Sheta, Lana , Kujan, Lynzey , Pema, Shahil , Ridd, Sarah , Spies, Nicholas C. , Andric, Veronica , Chiorean, Andreea , Rieke, Damian , Clark, Kaitlin A., Reisle, Caralyn , Venigalla, Ajay C, Jani, Payal , Takahashi, Hideaki , Suda, Avila, Horak, Peter , Ritter, Deborah , DeLong, Sean , Lamping, Mario , Shen, Haolin , Marr, Alexander , Hoang, My , Singhal, Kartik , Khanfar, Mariam , Li, Brian V , Lin, Wan‐Hsin , Terraf, Panieh, Corson, Laura , Salama, Yasser, Farncombe, Kirsten M. , Ji, Jianling , Zhao, Xiaonan, Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Walker, Jason , Zhang, Jinghui , Patel, Ronak Y. , Kim, Raymond H. , Jones, Steven J.M. , Raca, Gordana , Madhavan, Subha , Griffith, Malachi , Griffith, Obi L. , Coffman, Adam C , Kiwala, Susanna , Zhou, Xin , Campbell, Katie M , Ji, Jianling , Cotto, Kelsy C , Schriml, Lynn M , Wagner, Alex H , Griffith, Malachi , Griffith, Obi L , Krysiak, Kilannin , Kanagal-Shamanna, Rashmi , Kim, Raymond H , Saliba, Jason , Barnell, Erica K. , Grisdale, Cameron J. , Lever, Jake , Venigalla, Ajay , Evans, Mark G. , Ainscough, Benjamin J. , Kesserwan, Chimene A. , Zhao, Xiaonan, King, Ian F. G. , Skidmore, Zachary L. , Milosavljevic, Aleksandar , Giles, Rachel H. , Mardis, Elaine R. , Rao, Shruti , Wagner, Alex H. , Khanfar, Mariam

Mayo Clinic

Nucleic Acids Research | October 15, 2022 | Volume: 51 | Issue: D1 | Pages: D1230-D1241

10.1093/nar/gkac979 | PMID 36373660 Get It

Abstract CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence Items) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new Evidence Types (Predisposing, Oncogenic and Functional). The growing CIViC knowledgebase has over 300 contributors and distributes clinically-relevant cancer variant data currently representing &gt;3200 variants in &gt;470 genes from &gt;3100 publications.
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.

Mayo Clinic

Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574

10.1097/mpa.0000000000002079 | PMID 36206460 Get It

Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.
Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group
Finnes, Heidi D. , Child, Berrie, DeFrates, Sean, Kinsman, Katharine, Thorne, Andrew, Lockhorst, Robin, Urmanski, Angela, Amin, Sapna, Barr, Hallie, Baviskar, Sunanda, Beckman, Carrie , Chow, Nicholas , Derba, Megan, Erickson, Marsha K., Hennes, Emily R , Heisey, Heather D., Limvorasak, Suwicha , Luckritz, Todd, Mays, Theresa A., Nzelibe, Chukwuemeka N, Romanowski, Tracy, Smith, Camille M. , Tesoro, Debra, Toeniskoetter, Katelyn, Voytilla, Krista, Lentz, Sarah, Murphy, Jennifer, Lau, Rebecca

Mayo Clinic

American Journal of Health-System Pharmacy | October 6, 2022 | Volume: 80 | Issue: 1 | Pages: e67-e73

10.1093/ajhp/zxac267 | PMID 36200957 Get It

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Johnson, Amanda M. , Barsky, Maria, Ahmed, Waseem , Zullow, Samantha, Galati, Jonathan S. , Jairath, Vipul , Narula, Neeraj , Peerani, Farhad , Click, Benjamin , Coburn, Elliot, Dang, ThucNhi T. , Garg, Rajat , Aggarwal, Manik , Mohammad, Danah, Halloran, Brendan P. , Kochhar, Gursimran , Todorowski, Hannah, Din, Nabeeha Mohy Ud, Izanec, James , Teeple, Amanda, Gasink, C, Muser, Erik, Ding, Zhijie , Lakhani, Komal, Hogan, Dan, Datta, Samit, Boland, Brigid S. , Bohm, Matthew , Fischer, Monika , Sagi, Sashidhar , Afzali, Anita , Ullman, Thomas, Lawlor, Garrett , Baumgart, Daniel C. , Chang, Shannon, Scherl, Ellen , Sandborn, William J. , Bruining, David H. , Kane, Sunanda V. , Loftus, Edward V. , Dulai, Parambir S. , Jairath, Vipul , Jairath, Vipul , Bruining, David, Jairath, V , Jairath, V , Loftus, Edward V , Jairath, Vipul , Gold, Stephanie Lauren , Agrawal, Manasi , Swaminath, Arun C. , Hogan, Dan, Ungaro, Ryan C. , Chang, Shannon, Hudesman, David , Lukin, Dana J. , Colombel, Jean‐Frédéric , Sands, Bruce E , Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

American Journal of Gastroenterology | October 3, 2022 | Volume: 118 | Issue: 2 | Pages: 317-328

10.14309/ajg.0000000000002047 | PMID 36191274 Get It

INTRODUCTION: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). METHODS: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients. Data included patient demographics, disease phenotype, disease activity, treatment history, and concomitant medications. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions were assessed using time-to-event analysis, and clinical predictors were assessed by using multivariate Cox proportional hazard analyses. Serious infections and adverse events were defined as those requiring hospitalization or treatment discontinuation. RESULTS: A total of 1,113 patients (51.8% female, 90% prior antitumor necrosis factor exposure) were included, with a median follow-up of 386 days. Cumulative rates of clinical, steroid-free, endoscopic, and radiographic remissions at 12 months were 40%, 32%, 39%, and 30%, respectively. Biologic-naive patients achieved significantly higher rates of clinical and endoscopic remissions at 63% and 55%, respectively. On multivariable analyses, prior antitumor necrosis factor (hazard ratio, 0.72; 95% confidence interval, 0.49–0.99) and vedolizumab exposure (hazard ratio, 0.65; 95% confidence interval, 0.48–0.88) were independently associated with lower likelihoods of achieving endoscopic remission. In patients who experienced loss of remission, 77 of 102 (75%) underwent dose optimization, and 44 of 77 (57%) achieved clinical response. An additional 152 of 681 patients (22.3%) were dose-optimized because of primary nonresponse incomplete response to UST, of whom 40.1% (61 of 152) responded. Serious infections occurred in 3.4% of patients while other noninfectious adverse events (lymphoma [n = 1], arthralgia [n = 6], rash [n = 6], headache [n = 3], hepatitis [n = 3], hair loss [n = 3], neuropathy [n = 1], and vasculitis [n = 1]) occurred in 2.4% of patients. DISCUSSION: UST represents a safe and effective treatment option for CD, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months. The greatest treatment effect of UST was seen in biologic-naive patients, and dose escalation may recapture clinical response.
Rapid Early Progression (REP) of Glioblastoma Is an Independent Negative Prognostic Factor: Results From a Systematic Review and Meta-Analysis
Hamer, Philip Witt De, Quiñones‐Hinojosa, Alfredo , Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , D’Urso, Pietro Ivo , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology | October 1, 2022 | Volume: 24 | Issue: Supplement_4 | Pages: iv14-iv14

10.1093/neuonc/noac200.062 Get It

Abstract AIMS In patients with newly-diagnosed glioblastoma, rapid early progression (REP) refers to tumour regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis aimed to appraise published data on REP to better characterise and understand this phenomenon. METHOD Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to 21/10/21. Studies describing the incidence of REP – tumour growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly-diagnosed glioblastoma, were included. The primary outcome was REP incidence. RESULTS From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0- 58.8 years). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1-1.5). The median number of days between MRI scans was 34 days (IQR 18-45 days). The mean incidence rate of REP was 45.9% (range 19.3%-72.0%) and significantly lower in studies employing functional imaging to define REP (p&lt;0.001). REP/non-REP groups were comparable with respect to age (p=0.99), gender (p=0.33) and time between scans (p=0.81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30-2.43, p&lt;0.001), shortened progression-free survival (HR 1.78, 95% CI 1.30-2.43, p&lt;0.001), subtotal resection (OR 6.96, 95% CI 4-51-10.73, p&lt;0.001) and IDH wildtype versus mutant tumours (OR 0.20, 95% CI 0.02-0.38, p=0.03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72-2.28, p=0.39). CONCLUSION REP occurs in almost half of patients with newly-diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Roofeh, David , Brown, Kevin M. , Kazerooni, Ella A. , Tashkin, Donald P. , Assassi, Shervin , Martínez, Fernando J. , Wells, Athol U. , Raghu, Ganesh , Denton, Christopher P. , Chung, Leland W.K. , Matteson, Eric L. , Pauling, John D , Seibold, James R. , Volkmann, Elizabeth R. , Walsh, Simon , White, Eric S. , Barratt, Shaney , Domsic, Robyn T. , Dellaripa, Paul F. , Rosas, Iván O. , Bhatt, Nitin, Hsu, Vivien , Kahaleh, Bashar , Garcha, Puneet , Khanna, Surabhi , Lin, Celia J. F., Mathai, Stephen C. , Doyle, Tracy J. , Steen, Virginia , Zoz, Donald F., Rodríguez‐Pintó, Ignasi , Lewandoski, Andrew, Belloli, Elizabeth A. , Lescoat, Alain , Nagaraja, Vivek , Ye, Wen , Huang, Suiyuan, Maher, Toby M. , Khanna, Dinesh , Tashkin, Donald , Martinez, Fernando , Chung, Lorinda , Hoffmann-Vold, Anna-Maria , Distler, Oliver , Johannson, Kerri A , Allanore, Yannick , Matteson, Eric L , Kawano-Dourado, Leticia , Pauling, John D , Seibold, James R , Volkmann, Elizabeth R , Oddis, Chester V , White, Eric S , Barratt, Shaney L , Bernstein, Elana J , Domsic, Robyn T , Dellaripa, Paul F , Conway, Richard , Rosas, Ivan , Hsu, Vivien , Ingegnoli, Francesca , Kahaleh, Bashar , Garcha, Puneet , Gupta, Nishant , Korsten, Peter , Strand, Vibeke , Steen, Virginia , Ovalles-Bonilla, Juan , Rodriguez-Pinto, Ignasi , Shenoy, Padmanabha D , Lescoat, Alain , Nagaraja, Vivek , Maher, Toby , Khanna, Dinesh , Assassi, Shervin , Mathai, Stephen C , Hoffmann‐Vold, Anna‐Maria , Distler, Oliver , Kawano-Dourado, Letícia , Oddis, Chester V. , Bernstein, Elana J. , Conway, Richard , Ingegnoli, Francesca , Gupta, Nishant , Korsten, Peter , Lewandoski, Andrew

Mayo Clinic

Rheumatology | September 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1877-1886

10.1093/rheumatology/keac557 | PMID 36173318 Get It

Abstract Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patie
Lehrer, Eric J. , Ahluwalia, Manmeet S. , Gurewitz, Jason , Bernstein, Kenneth , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Fakhoury, Kareem , Rusthoven, Chad G. , Mathieu, David , Trudel, Claire, Malouff, Timothy D. , Bonney, Phillip A. , Hwang, Lindsay , Zada, Gabriel , Patel, Samir , Deibert, Christopher P., Franzini, Andrea , Attuati, Luca , Prasad, Rahul N. , Raval, Raju R. , Lee, Cheng‐Chia , Green, Sheryl , Sheehan, Jason P. , Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Yu, Cheng‐Ping , Picozzi, Piero , Palmer, Joshua D. , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | September 16, 2022 | Volume: 138 | Issue: 5 | Pages: 1178-1187

10.3171/2022.7.jns22752 | PMID 36115055 Get It

OBJECTIVE Immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) are commonly utilized in the management of brain metastases. Treatment-related imaging changes (TRICs) are a frequently observed clinical manifestation and are commonly classified as imaging-defined radiation necrosis. However, these findings are not well characterized and may predict a response to SRS and ICIs. The objective of this study was to investigate predictors of TRICs and their impact on patient survival. METHODS This retrospective multicenter cohort study was conducted through the International Radiosurgery Research Foundation. Member institutions submitted de-identified clinical and dosimetric data for patients with non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) brain metastases that had been treated with SRS and ICIs. Data were collected from March 2020 to February 2021. Univariable and multivariable Cox and logistic regression analyses were performed. The Kaplan-Meier method was used to evaluate overall survival (OS). The diagnosis-specific graded prognostic assessment was used to guide variable selection. TRICs were determined on the basis of MRI, PET/CT, or MR spectroscopy, and consensus by local clinical providers was required. RESULTS The analysis included 697 patients with 4536 brain metastases across 11 international institutions in 4 countries. The median follow-up after SRS was 13.6 months. The median age was 66 years (IQR 58–73 years), 54.1% of patients were male, and 57.3%, 36.3%, and 6.4% of tumors were NSCLC, melanoma, and RCC, respectively. All patients had undergone single-fraction radiosurgery to a median margin dose of 20 Gy (IQR 18–20 Gy). TRICs were observed in 9.8% of patients. The median OS for all patients was 24.5 months. On univariable analysis, Karnofsky Performance Status (KPS; HR 0.98, p < 0.001), TRICs (HR 0.67, p = 0.03), female sex (HR 0.67, p < 0.001), and prior resection (HR 0.60, p = 0.03) were associated with improved OS. On multivariable analysis, KPS (HR 0.98, p < 0.001) and TRICs (HR 0.66, p = 0.03) were associated with improved OS. A brain volume receiving ≥ 12 Gy of radiation (V12Gy) ≥ 10 cm3 (OR 2.78, p < 0.001), prior whole-brain radiation therapy (OR 3.46, p = 0.006), and RCC histology (OR 3.10, p = 0.01) were associated with an increased probability of developing TRICs. The median OS rates in patients with and without TRICs were 29.0 and 23.1 months, respectively (p = 0.03, log-rank test). CONCLUSIONS TRICs following ICI and SRS were associated with a median OS benefit of approximately 6 months in this retrospective multicenter study. Further prospective study and additional stratification are needed to validate these findings and further elucidate the role and etiology of this common clinical scenario.
Cricopharyngeus Muscle Dysfunction and Hypopharyngeal Diverticula (e.g., Zenker): A Multicenter Study
Howell, Rebecca J. , Ekbom, Dale C. , Kasperbauer, Jan L. , Tabangin, Meredith E. , Altaye, Mekibib , Wahab, Shaun A. , Belafsky, Peter C. , Allen, Jacqui , Bayan, Semirra L. , Cervenka, Brian , deSilva, Brad W. , Friedman, Aaron D. , Fritz, Mark A. , Giliberto, John Paul , Harmon, Jeffrey , Khosla, Sid , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Piraka, Cyrus , Rosen, Clark A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Yuen, Sonia , Postma, Greg, Ekbom, Dale , Kasperbauer, Jan , Tabangin, Meredith , Belafsky, Peter , Bayan, Semirra, Giliberto, John Paul , Bayan, Semirra , Dion, Gregory R. , Guardiani, Elizabeth , Kwak, Paul E. , Ma, Yue , Mayerhoff, Ross , Wilson, Keith, Wright, Carter

Mayo Clinic

The Laryngoscope | September 14, 2022 | Volume: 133 | Issue: 6 | Pages: 1349-1355

10.1002/lary.30387 | PMID 36102298 Get It

ObjectiveTo describe demographics and imaging and compare findings and symptoms at presentation in a large cohort of persons with cricopharyngeus muscle dysfunction (CPMD) with and without hypopharyngeal diverticula.MethodologyProspective, multicenter cohort study of all individuals enrolled in the Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH) Collaborative. Patient survey, comorbidities, radiography, laryngoscopy findings, and patient‐reported outcome measures (e.g., Eating Assessment Tool [EAT‐10]) data were abstracted from a REDCap database and summarized using means, medians, percentages, and frequencies. Diagnostic categories were compared using analysis of variance.ResultsA total of 250 persons were included. The mean age (standard deviation [SD]) of the cohort was 69.0 (11.2). Forty‐two percent identified as female. Zenker diverticula (ZD) was diagnosed in 85.2%, 9.2% with CPMD without diverticula, 4.4% with a Killian Jamieson diverticula (KJD), and 1.2% traction‐type diverticula. There were no differences between diagnostic categories in regard to age, gender, and duration of symptoms (p = 0.25, 0.19, 0.45). The mean (SD) EAT‐10 score for each group was 17.1 (10.1) for ZD, 20.2 (9.3) for CPMD, and 10.3 (9.4) for KJD. Patients with isolated CPMD had significantly greater EAT‐10 scores compared to the other diagnostic groups (p = 0.03).ConclusionZD is the most common, followed by CPMD without diverticula, KJD, and traction‐type. Patients with isolated obstructing CPMD may be more symptomatic than persons with ZD or KJD.Level of Evidence4 Laryngoscope, 133:1349–1355, 2023